FDA

Genetic engineering concept
#AskBio #FDA #Gene therapy #Neuroscience #Parkinson's

Further FDA support for Parkinson’s gene therapy

AskBio’s investigational gene therapy AB-1005 for the treatment of Parkinson’s disease (PD) has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the US Food and Drug Administration (FDA).  The FDA decision follows a review of information and data provided by AskBio, including clinical evidence from the open label Phase… Read More

#News #Regulatory

FDA
#Boehringer Ingelheim #FDA #Non-small cell lung cancer (NSCLC) #Oncology

Targeted medicine for NSCLC receives FDA Priority Review

The US Food and Drug Administration (FDA) has granted Priority Review to Boehringer Ingelheim’s new drug application for zongertinib for unresectable or metastatic non-small cell lung cancer (NSCLC).  It is indicated for adult patients whose tumours have HER2 (ERBB2) mutations and who have received prior systemic therapy.   Under Priority Review,… Read More

#News #Regulatory

Monoclonal antibody
#Dermatology #FDA #Monoclonal antibodies #Orphan drugs #Rare disease

Dupixent for bullous pemphigoid under FDA priority review

The US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults with bullous pemphigoid (BP).  The sBLA is supported by data from a pivotal study evaluating the efficacy and safety of Dupixent in 106 adults with moderate-to-severe… Read More

#News #Regulatory

#Addiction #Fast Track designation #FDA #PleoPharma

FDA fast-tracks drug for cannabis withdrawal syndrome

PleoPharma has secured US Food and Drug Administration (FDA) Fast Track designation for PP-01, its lead asset for the mitigation of cannabis withdrawal syndrome in patients with cannabis use disorder.  "We are pleased that PP-01 has been granted Fast Track designation and are grateful to the FDA for recognising the… Read More

#News #Regulatory

Small cell lung cancer
#Ariceum Therapeutics #FDA #Lung cancer #Oncology #Orphan drugs #Radiopharmaceuticals

Radiopharmaceutical cancer therapy granted orphan drug status

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Ariceum Therapeutics’ 225Ac-SSO110 (satoreotide) for the treatment of patients with small cell lung cancer (SCLC).  Ariceum has announced plans to commence Phase I/II human clinical development of 225Ac-satoreotide under the trial name, SANTANA-225 in Q1 2025. … Read More

#News #Regulatory

Approval stamp
#Alopecia #Alys Pharmaceuticals #Clinical trials #FDA #Health Canada #Investigational New Drug (IND)

Clearance for first genetic medicine programme in dermatology

The US Food and Drug Administration (FDA) and Health Canada have cleared Alys Pharmaceuticals’ Investigational New Drug (IND) / Clinical Trial Application (CTA) for the study of ALY-101 in patients suffering from Alopecia Areata (AA). The Phase IIa trial will evaluate the safety and efficacy of ALY-101, an intradermal injectable… Read More

#News #Regulatory

CAR-T therapy
#Allogene Therapeutics #Autoimmune disease #CAR-T #Cell therapy #FDA #Phase I trial

Allogeneic CAR-T therapy gets go-ahead for rheumatology trial

Allogene Therapeutics has been given the green light from the US Food and Drug Administration (FDA) for a rheumatology basket study of ALLO-329, an investigational allogeneic CAR-T product.  The Phase I RESOLUTION basket trial will evaluate the safety and preliminary efficacy of ALLO-329 in patients with systemic lupus erythematosus, including… Read More

#Cancer Research #News #Regulatory

CAR-T therapy for leukaemia
#CAR-T #Cell therapy #FDA #Haematology #March Biosciences #Oncology

FDA Orphan Drug Designation for CD5 CAR-T cell therapy

The US Food and Drug Administration (FDA) has granted orphan drug designation to MB-105, March Biosciences’ CD5-targeted CAR-T cell therapy for the treatment of relapsed/refractory CD5-positive T-cell lymphoma (TCL).  MB-105 is in development as a treatment for TCL, T-cell acute lymphoblastic leukaemia (T-ALL), chronic lymphocytic leukaemia (CLL), and mantle cell… Read More

#News #Regulatory

#Digital therapeutics #Drug development #FDA #Regulatory

Streamlining the development of digital therapeutics

Acacia Parks, PhD, MBA, Advisor to Lindus Health, discusses the journey to commercialisation for digital therapeutics and how best to engage the FDA in this process.  While there is no “one size fits all” approach to the development of any class of treatments, this is especially true for digital therapeutics… Read More

#Exclusive Content

Cancer cells
#Antibody drug conjugate (ADC) #AstraZeneca #Breast cancer #Daiichi Sankyo #FDA #Oncology

FDA approved ADC improves breast cancer survival by 37%

The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan-dlnk (Datroway) a Trop-2-directed antibody and topoisomerase inhibitor conjugate, as a treatment for breast cancer.  The decision was based on the results of the Phase III TROPION-Breast01 trial which showed a 37% reduction in the risk of disease progression or… Read More

#News #Regulatory

FDA
#AstraZeneca #FDA #Lymphoma #Oncology

First US approval for first-line BTK inhibitor for mantle cell lymphoma

The US Food and Drug Administration (FDA) has granted approval to acalabrutinib (Calquence) with bendamustine and rituximab for adults with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT).  The regulator also granted approval to acalabrutinib as a single agent for adults with… Read More

#News #Regulatory #Trending News

#Autism #Fast Track designation #FDA #Neuroscience #Spinogenix

FDA fast-tracks drug for autism cause Fragile X syndrome

The US Food and Drug Administration (FDA) has granted Fast Track designation to SPG601 for the treatment of people with Fragile X syndrome (FXS).  FXS, a known cause of autism, is the leading inherited form of intellectual disability that can produce a wide range of disabling symptoms, with many individuals… Read More

#News #Regulatory

Tau proteins
#Alzheimer's #Fast Track designation #FDA #Johnson & Johnson #Monoclonal antibodies #Neuroscience

Tau-directed mAb receives US FDA fast track designation

The US Food and Drug Administration (FDA) has granted Fast Track designation to posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb).  The therapy from Johnson & Johnson is being investigated to treat patients with early Alzheimer’s disease (AD) in the Phase IIb AuTonomy study.   It has shown potential in targeting disease-associated… Read More

#News #Regulatory

#Artificial intelligence (AI) #Drug discovery #FDA #Regulatory

FDA issues first guidance on the use of AI in drug development

The US Food and Drug Administration (FDA) has issued the first guidance on the use of artificial intelligence (AI) for the development of drug and biological products.  The draft guidance provides recommendations on the use of AI to support a regulatory decision about a drug or biological product’s safety, effectiveness… Read More

#News #Regulatory #Trending News

FDA
#Antibiotic resistance #Antibiotics #FDA #MicuRx Pharmaceutical #Orphan drugs

Novel benzoxazole antibiotic gets FDA Orphan Drug Designation

MicuRx Pharmaceutical’s anti-infection drug MRX-5 has been granted Orphan Drug Designation (ODD) by the US Food and Drug Administration (FDA) for the treatment of non-tuberculous mycobacteria (NTM) infections.  MRX-5 is a novel benzoxazole antibiotic developed for the treatment of mycobacteria infections, particularly infections caused by non-tuberculous Mycobacteria (NTM).   In recent… Read More

#News #Regulatory

B-cells in multiple myeloma
#Cancer immunotherapy #FDA #MAIA Biotechnology #Paediatrics #Rare disease

Telomere-targeting agent granted Rare Pediatric Disease designation

The US Food and Drug Administration (FDA) has designated MAIA Biotechnology’s immunotherapy THIO for the treatment of paediatric-type diffuse high-grade gliomas (PDHGG) as a drug for a rare paediatric disease. “THIO is a versatile anti-cancer agent that has demonstrated positive results in multiple difficult to treat cancer types, including paediatric… Read More

#Cancer Research #News